Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Defined term · Pharmacology

DPP-4

Dipeptidyl peptidase-4, the protease that cleaves native glucagon-like peptide-1 within minutes. Every long-acting analogue in this set is protected against it structurally.

Document identifier
CEI-GT-128
Series
Defined term
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1DPP-4

§1.1Also known as

Dipeptidyl peptidase-4

§1.2Category

Pharmacology — Terms describing how a compound acts and how the body handles it.

§1.3Related terms

  • Enzymatic degradation — Breakdown of a peptide by proteases, principally dipeptidyl peptidase-4 for incretins. Resistance is engineered by substitution at the cleavage site.
Compound Evidence Institute · CEI-GT-128 · https://compoundevidence.com/glossary/dpp-4/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.